ResMed Inc.— Sankey Diagram
Quarterly mode · period ending 2026-03-31 · SEC EDGAR
ComparingFY2026 (Q4) vs FY2025 (Q4)
Revenue
$1.43B
↑+10.8% +$140Mvs FY2025 (Q4)
Gross Profit
$891M
↑+16.3% +$125Mvs FY2025 (Q4)
Operating Income
$500M
↑+17.3% +$74Mvs FY2025 (Q4)
Net Income
$399M
↑+9.2% +$34Mvs FY2025 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 (Q4) | FY2025 (Q4) |
|---|---|---|
| Revenue | $1.43B | $1.29B |
| COGS | $540M | $525M |
| Gross Profit | $891M | $766M |
| R&D | $94M | $84M |
| SG&A | $286M | $245M |
| D&A | $11M | $11M |
| Other OpEx | $0 | $0 |
| Operating Income | $500M | $426M |
| Interest Exp. | $12M | $793K |
| Other Non-Op | $0 | $8M |
| Pretax Income | $488M | $418M |
| Tax | $89M | $53M |
| Net Income | $399M | $365M |
QuarterCharts · SEC EDGAR data · RMD · Comparing FY2026 (Q4) vs FY2025 (Q4)